A multi-centre prospective study for using lauromacrogol for ablation of pancreatic cystic neoplasms with the aid of EUS

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023913

Enrollment

Unknown

Registered

2019-06-18

Start date

2019-06-20

Completion date

Unknown

Last updated

2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cystic neoplasms

Interventions

Experimental group: lauromacrogol for ablation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with pancreatic cystic tumors were examined by imaging examination at the hospital; (2) Imaging diagnosis of pancreatic cystic tumors with a diameter of =10.0 mm; (3) Signing of informed consent;

Exclusion criteria

Exclusion criteria: (1) those who have contraindications to anesthesia; (2) those who have contraindications for endoscopy; (3) those with coagulopathy or cardiopulmonary dysfunction; (4) those with evidence of acute pancreatitis or pancreatic infection; (5) cannot exclude malignant; (6) patients with pancreatic pseudocyst and SPNs.

Design outcomes

Primary

Measure	Time frame
size of the cyst before and after ablation;volume of the cyst before and after ablation;	—

Secondary

Measure	Time frame
amylase and lipase;	—

Countries

China

Contacts

Public ContactEnqiang Linghu

The First Medical Center of Chinese PLA General Hospital

linghuenqiang@vip.sina.com+86 13501233558

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026